share_log

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Mahatme Sandesh

SEC announcement ·  May 30 16:34
Summary by Moomoo AI
Sandesh Mahatme, a director and 10% owner of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 30, 2024. The filing, submitted on Form 3, indicates Mahatme's beneficial ownership of non-derivative securities, specifically 26,000 common shares of CRISPR Therapeutics, which are subject to a stock option right to buy at a price of $44.81 per share. The option was granted on October 16, 2023, and is set to vest over 36 months, with the first installment vesting on November 16, 2023. The form was filed as a single reporting person and included a Power of Attorney signed by Sandesh Mahatme.
Sandesh Mahatme, a director and 10% owner of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 30, 2024. The filing, submitted on Form 3, indicates Mahatme's beneficial ownership of non-derivative securities, specifically 26,000 common shares of CRISPR Therapeutics, which are subject to a stock option right to buy at a price of $44.81 per share. The option was granted on October 16, 2023, and is set to vest over 36 months, with the first installment vesting on November 16, 2023. The form was filed as a single reporting person and included a Power of Attorney signed by Sandesh Mahatme.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more